Indian Journal of Nephrology Home 

LETTER TO EDITOR
[Download PDF]
Year : 2009  |  Volume : 19  |  Issue : 3  |  Page : 126-

Kidney transplantation in a patient with HIV disease

LI Gonzalez-Granado 
 Immunodeficiencies Unit, Hospital 12 de Octubre, Avenida Andalucia S/N, 28041, Madrid, Spain

Correspondence Address:
L I Gonzalez-Granado
Calle Pizarro 2, 3 deRecha. 47006, Valladolid
Spain

How to cite this article:
Gonzalez-Granado L I. Kidney transplantation in a patient with HIV disease.Indian J Nephrol 2009;19:126-126

How to cite this URL:
Gonzalez-Granado L I. Kidney transplantation in a patient with HIV disease. Indian J Nephrol [serial online] 2009 [cited 2022 Nov 30 ];19:126-126
Available from: https://www.indianjnephrol.org/text.asp?2009/19/3/126/57113

Full Text

Sir,

I have read with great interest the article from Bansai et al. [1] I agree that we are now able to offer good alternatives to HIV patients transplanting kidney or liver apart from conservative management. However, I disagree with the antiretroviral regimen. It is well known that new PI΄s are preferable than old ones and nevirapine. [2] The only point is that you need to check serum antiretroviral levels at least for several weeks after kidney transplantation in order to achieve a suitable dose and dose interval. For instance, with lopinavir/ritonavir (LPV/r), frequently a more prolonged interval of dose and dose lowering is needed. Today, nevirapine is used only in children below 6 months of age, women with CD4 count below 250 cells/mm 3 and men with less than 400 cells/mm 3 . With higher CD4 count, severe hepatotoxicity has been described. In some cases, hepatic injuries continued to progress despite discontinuation of nevirapine. [3] International guidelines do not recommend the regimen for this patient. [4],[5]

I would like to emphasize that serum levels of antiretroviral drugs may help to achieve the best outcome for kidney transplantation in HIV patients.

References

1Bansal SB SM, Ahlawat R, Kher V. Kidney transplantation in a patient with HIV disease. Indian J Nephrol 2009;19:77-9.
2Crane H, Van Rompaey S, Kitahata M. Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine. AIDS Patient Care STDS 2007;21:920-9.
3Baylor M, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004;35:538-9.
4Who library cataloguing-in-publication data. Antiretroviral therapy for hiv infection in adults and adolescents: recommendations for a public health approach. Available from http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf . [last accessed on 2006 Jul 10].
5Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3. Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Last accessed on 2008 Jul 10].